PFE vs. TEVA: Pfizer vs. Teva Pharmaceutical Stock Comparison
How do Pfizer (PFE) and Teva Pharmaceutical (TEVA) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Pfizer (PFE) and Teva Pharmaceutical (TEVA) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.
Pfizer (PFE) trades as ordinary local shares, while Teva Pharmaceutical (TEVA) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | PFE | TEVA |
|---|---|---|
| Name | Pfizer Inc. | Teva Pharmaceutical Industries Ltd. ADR |
| Country/Region | United States | Israel |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Pharmaceuticals |
| GICS Sub-Industry | Pharmaceuticals | Pharmaceuticals |
| Market Capitalization | 167.52 billion USD | 49.72 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | June 1, 1972 | February 16, 1982 |
| Security Type | Common Stock | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | PFE | TEVA |
|---|---|---|
| Total Return (1Y) | 28.65% | 79.58% |
| Total Return (3Y, Annualized) | 6.41% | 69.94% |
| Total Return (5Y, Annualized) | -3.98% | 35.86% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | PFE | TEVA |
|---|---|---|
| Volatility (1Y, Annualized) | 21.72% | 33.95% |
| Beta (5Y) | 0.35 | 0.96 |
| Max Drawdown (5Y) | -58.96% | -43.70% |
| Avg. Volume (3M) | 33.67M | 5.91M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | PFE | TEVA |
|---|---|---|
| Sharpe Ratio (1Y) | 1.12 | 2.22 |
| Sortino Ratio (1Y) | 1.73 | 3.94 |
Profitability
ROE (TTM)
Teva Pharmaceutical (TEVA) at 6.65% sits in the top ROE quartile, while Pfizer (PFE) at 4.47% is closer to the peer norm — stronger capital efficiency for TEVA.
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.47%
- Max
- 109.18%
- Q3
- 6.23%
- PFE
- 4.47%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.65%
- Max
- 109.18%
- TEVA
- 6.65%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Pfizer (PFE) at 6.34% retains a top-quartile share of revenue as profit, ahead of Teva Pharmaceutical (TEVA) at 2.94%, which keeps about the industry-typical share.
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.34%
- Max
- 18.05%
- PFE
- 6.34%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.94%
- Max
- 18.05%
- Q3
- 4.78%
- TEVA
- 2.94%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Pfizer (PFE) at 33.38% and Teva Pharmaceutical (TEVA) at 27.40% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.38%
- Max
- 83.12%
- PFE
- 33.38%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.40%
- Max
- 83.12%
- TEVA
- 27.40%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | PFE | TEVA |
|---|---|---|
| ROE (TTM) | 4.47% | 6.65% |
| ROA (TTM) | 5.59% | 5.35% |
| Net Margin (TTM) | 6.34% | 2.94% |
| Operating Margin (TTM) | 33.38% | 27.40% |
| Gross Margin (TTM) | 74.90% | 53.51% |
Growth
Revenue Growth
Teva Pharmaceutical (TEVA) at 4.31% is around its peer norm for revenue growth, while Pfizer (PFE) at -1.65% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Only one side can be read here: Pfizer (PFE) reports EPS growth of -3.55%, ranked against its industry; Teva Pharmaceutical (TEVA) has no EPS growth figure this period.
Growth Metrics
| Metric | PFE | TEVA |
|---|---|---|
| Revenue Growth (YoY) | -1.65% | 4.31% |
| Revenue Growth (3Y CAGR) | -14.80% | 4.96% |
| EPS Growth (YoY) | -3.55% | -- |
| EPS Growth (3Y CAGR) | -37.12% | -- |
Financial Strength
Current Ratio (MRQ)
Both Pfizer (PFE) at 1.42 and Teva Pharmaceutical (TEVA) at 0.95 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.42
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- PFE
- 1.42
- Min
- 0.10
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.95
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- TEVA
- 0.95
- Min
- 0.10
Debt / Equity (MRQ)
Both balance sheets lean debt-heavy versus peers, but TEVA is more stretched: Pfizer (PFE) at 0.71 sits in the higher-leverage quartile and Teva Pharmaceutical (TEVA) at 2.13 is above its industry benchmark range.
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.71
- Max
- 1.42
- PFE
- 0.71
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.13
- TEVA
- 2.13
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | PFE | TEVA |
|---|---|---|
| Current Ratio (MRQ) | 1.42 | 0.95 |
| Debt / Equity (MRQ) | 0.71 | 2.13 |
| Net Debt / EBITDA | 1.97 | 2.93 |
Dividends
Dividend Yield (TTM)
Teva Pharmaceutical (TEVA) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Pfizer (PFE) reports a yield of 7.30%, ranking against industry peers normally.
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.30%
- PFE
- 7.30%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEVA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Pfizer (PFE) reports payout ratio above 100% at 245.71%, meaning dividends exceeded current-period earnings; Teva Pharmaceutical (TEVA) pays no dividend (payout 0.00%).
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
245.71%
- PFE
- 245.71%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEVA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | PFE | TEVA |
|---|---|---|
| Dividend Yield (TTM) | 7.30% | 0.00% |
| Dividend Payout Ratio (TTM) | 245.71% | 0.00% |
Valuation
P/E Ratio (TTM)
Pfizer (PFE) at 41.99 is near its industry’s usual P/E ratio, while Teva Pharmaceutical (TEVA) at 99.09 sits above its peer range — an unusually expensive price for TEVA’s trailing earnings.
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
41.99
- Max
- 85.34
- Q3
- 43.46
- PFE
- 41.99
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
99.09
- TEVA
- 99.09
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Both Pfizer (PFE) at 2.63 and Teva Pharmaceutical (TEVA) at 2.89 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.63
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- PFE
- 2.63
- Min
- 0.01
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.89
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- TEVA
- 2.89
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Pfizer (PFE) at 1.88 and Teva Pharmaceutical (TEVA) at 6.23 are valued close to their industries’ norm against book — neither stands out from peers.
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.88
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- PFE
- 1.88
- Q1
- 1.69
- Min
- -5.59
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.23
- Max
- 13.53
- Q3
- 6.54
- TEVA
- 6.23
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | PFE | TEVA |
|---|---|---|
| P/E Ratio (TTM) | 41.99 | 99.09 |
| P/S Ratio (TTM) | 2.63 | 2.89 |
| P/B Ratio (MRQ) | 1.88 | 6.23 |
| Free Cash Flow Yield (TTM) | 7.76% | 3.00% |